[Table/Fig-1]:
Extent of Complete Haematological response (CHR) during sequential follow up in CML patients on Imatinib.
| ≤1 month | 3 months | 6 months | 12 months | |
|---|---|---|---|---|
| Total patients | 70 | 70 | 56 | 56 |
| CHR | 47.1% (33/70) | 80% (56/70) | 85.4% (48/56) | 90.4% (50/56) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.